Results 141 to 150 of about 58,391 (264)

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference. [PDF]

open access: yesBlood Neoplasia
Lustig M   +29 more
europepmc   +1 more source

Long‐Acting Cabotegravir/Rilpivirine Reduces Immune‐Activation and ‐Senescence in People With HIV With CMV Co‐Infection

open access: yesImmunology, Volume 179, Issue 1, Page 138-148, September 2026.
This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani   +16 more
wiley   +1 more source

The Host NADase CD38 Promotes JEV Replication by Targeting the NAD+/SIRT1 Axis. [PDF]

open access: yesMicroorganisms
Yang Y   +9 more
europepmc   +1 more source

Decoding the Black Box of Fish Vaccines Efficacy in Basic and Applied Contexts

open access: yesReviews in Aquaculture, Volume 18, Issue 4, September 2026.
ABSTRACT Vaccines are the frontline defense in aquaculture, yet predicting their real‐world performance remains a tricky puzzle. Unlike terrestrial veterinary vaccines, fish vaccines largely operate through “Black Box” processes, where we observe the outcomes but rarely understand the underlying immune mechanisms. Laboratory trials, though informative,
Jiří Kyslík   +2 more
wiley   +1 more source

Vitamin B3 (Nicotinamide) Supplementation in Primary and Scleroderma‐Related Raynaud Phenomenon

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective The aim of this study was to explore if vitamin B3 (nicotinamide) supplementation is a safe and effective adjunctive therapy for patients with primary Raynaud phenomenon (RP) and scleroderma‐related RP. The effect of nicotinamide supplementation in human patients with RP has not been studied before.
Mogeshni Govender   +8 more
wiley   +1 more source

Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas. [PDF]

open access: yesSci Rep
Dupuy A   +14 more
europepmc   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

open access: yesAdvanced Science, Volume 13, Issue 44, 7 August 2026.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng   +5 more
wiley   +1 more source

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma. [PDF]

open access: yesHemasphere
Raoof R   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy